JB Chemicals & Pharmaceuticals has reported 13 per cent rise in revenue after tax at Rs 111 crore for the second quarter ended September 30, 2022.
The drug agency had logged a revenue after tax (PAT) of Rs 98 crore in July-September interval of earlier fiscal 12 months.
Income rose to Rs 809 crore within the interval beneath evaluation as in contrast with Rs 593 crore within the year-ago quarter, it stated in a press release.
“Our market-beating efficiency in home enterprise was sustained via progress in our natural portfolio, with large manufacturers getting larger; and important demand acceleration in acquired manufacturers which have seamlessly transitioned in a brief interval,” firm CEO and Wholetime Director Nikhil Chopra stated.
The momentum within the worldwide enterprise continued throughout markets, with all three of the corporate’s verticals performing effectively, he added.
“Our strategic give attention to key manufacturers, segments and geographies is leading to a constant, sustained income progress.
“And this progress, together with productiveness enchancment and price optimisation initiatives, is creating robust working leverage which is enabling us to keep up our margins in an inflationary atmosphere with provide chain challenges,” Chopra stated.
(Solely the headline and movie of this report might have been reworked by the Enterprise Customary employees; the remainder of the content material is auto-generated from a syndicated feed.)
